Myogane, a small molecule drug is used as a neuro-protectant treatment of glaucoma, which is a neurodegenerative disease of the eye affecting.
Current treatments of glaucoma are predominantly targeted at reducing intra ocular pressure within the eye, however the remains a major unmet medical need for treatments which can slow the underlying neurodegenerative disease process.
Myogane has showed neuro-protective and neuro-restorative effects in many neuronal cell types including retinal ganglion cells.
Myogane works through the modulation of neurotrophic factors, naturally occurring proteins which protect and promote the growth of neurones.
The drug has demonstrated good oral bioavailability when dosed once daily in Phase I studies.